抗α干扰素中和抗体：接受不同干扰素制剂治疗患者中的相对发生率
Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.
作者信息
Antonelli G, Currenti M, Turriziani O, Dianzani F
机构信息
Institute of Virology, University, La Sapienza, Rome, Italy.
出版信息
J Infect Dis. 1991 Apr;163(4):882-5. doi: 10.1093/infdis/163.4.882.
The frequencies of antibody development so far reported in patients treated with different interferons (IFNs) are not readily comparable because of differences in treatment regimens and assay methods. Thus the frequency of neutralizing antibody development was analyzed in a large sample of sera derived from a relatively homogeneous group of patients treated with different IFN-alpha preparations. The frequency of developing neutralizing antibody to IFN varied according to the IFN given. Particularly, the seroconversion frequency was significantly higher in patients treated with recombinant IFN-alpha 2a (20.2%) than in patients treated with either recombinant IFN-alpha 2b (6.9%) or IFN-alpha N1 (1.2%), a lymphoblastoid IFN-alpha. Furthermore, sera obtained from patients treated with either recombinant IFN neutralized both types of recombinant IFNs but failed to neutralize IFN-alpha N1.
由于治疗方案和检测方法的差异，目前报道的接受不同干扰素（IFN）治疗的患者中抗体产生的频率难以直接比较。因此，对来自接受不同α-干扰素制剂治疗的相对同质患者群体的大量血清样本进行了中和抗体产生频率的分析。产生针对IFN的中和抗体的频率因所给予的IFN而异。特别是，接受重组α-干扰素2a治疗的患者（20.2%）的血清转化率显著高于接受重组α-干扰素2b（6.9%）或淋巴母细胞样α-干扰素N1（1.2%）治疗的患者。此外，接受任何一种重组干扰素治疗的患者的血清可中和两种重组干扰素，但不能中和α-干扰素N1。
Zotero 插件